NCT05397769View on ClinicalTrials.gov

Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial.

PHASE2RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

June 8, 2022

Primary Completion Date

June 1, 2026

Study Completion Date

December 31, 2026

Conditions
Locally Advanced Nasopharyngeal CarcinomaEnvafolimabInduction ChemotherapyPD-L1
Interventions
DRUG

Envafolimab Plus Chemoradiotherapy

Envafolimab was administrated with 300mg each time, every three weeks for a total of 22 cycles since the first day of induction chemotherapy.

Trial Locations (1)

510060

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER